Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript [Seeking Alpha]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Seeking Alpha
Sheldon Koenig - President, CEO & Director John Harlow - Chief Commercial Officer Benjamin Halladay - Chief Financial Officer Betty Swartz - Chief Business Officer Conference Call Participants Dan Bloomfield Yuchen Ding - Jefferies LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Serge Belanger - Needham & Company, LLC, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Presentation Operator Hello, ladies and gentlemen, thank you for standing by. Welcome to Esperion Therapeutics Strategic Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to Mr. Sheldon Koenig, President and Chief Executive Officer. Please go ahead, sir. Sheldon Koenig President, CEO & Director Thank you
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference [Yahoo! Finance]Yahoo! Finance
- Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics [Yahoo! Finance]Yahoo! Finance
- Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsGlobeNewswire
- Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)GlobeNewswire
- Esperion to Participate in 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
ESPR
Earnings
- 3/10/26 - Miss
ESPR
Sec Filings
- 4/16/26 - Form ARS
- 4/16/26 - Form DEFA14A
- 4/16/26 - Form DEF
- ESPR's page on the SEC website